Skip to content Skip to footer
Subscribe Now
In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2's smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment from the US government to scale the domestic manufacturing of their vaccine vials which are made from a new material that they spent the past 10+ years and $500M developing SiO2 have delivered the government enough vials to support 100M COVID-19 vaccine doses SiO2's Alabama facility went from manufacturing 10M vials per year to over 10M vials per month and their local workforce grew from 100 employees to over 500. Each vial manufactured by SiO2 is multi-dose and can hold anywhere from 8-10 doses of vaccine Tuba: Shed some light on SiO2 efforts in scaling up the manufacturing of vials to combat COVID-19. How do you feel being a part of Operation Warp Speed? Lawrence: It's been an honor to be part of this concept. The idea to help rebuild the critical medical infrastructure in the united states is great. The company is excited to help lead these efforts. We have added more than 500 new jobs, build new sophisticated manufacturing plants, and invented new technology. All of this is homegrown in the United States. Tuba: Discuss the funding received by the company from the US Government? How did this funding help in scaling up the manufacturing of their vaccine vials? Lawrence: We have received an investment from the US Government for $143 million. This is to help scale-out technology and manufacturing in support of the current and future pandemics. We have used this to build capacity to support more than 1 billion doses of vaccine. Tuba: How are SiO2's smart vials different from the traditional vials? Can we have a glance on the material used in the vials? Lawrence: https://www.youtube.com/watch?v=B_zBSS_XVCE Source: SiO2 Tuba: Can we have a glance on SiO2's patented barrier technology? Lawrence: The interior of the vial is covered with the barrier system coating, using plasma-enhanced chemical vapor deposition. A partially ionized gas mixture deposits a crystal-clear and ultra-thin barrier system that is covalently bonded to the polymer. The bond is so strong that the barrier system is rendered unremovable irrespective of chemical, thermal, or mechanical stress. The most interior protective layer is in direct contact with the vial's contents and is made of an organosilica material that is a mixture of silicon, oxygen, carbon, and hydrogen atoms. This patented composition was designed to resist dissolving in extremely high pH formulations, unlike ordinary glass. It also eliminates metal ions leaching into the drug formulation at extremely low pH formulations. The glass-like barrier layer is composed of pure silicon dioxide. This layer is extremely dense, which is an important characteristic of a barrier to oxygen, moisture, and other chemical compounds. And the final layer is composed of organosilica that creates a strong chemical bond to the plastic exterior and to the adjacent barrier layer. Tuba: What are the benefits of using SiO2's smart vials? Lawrence: SiO2 Materials Science's ready-to-use vial is the first of its kind, utilizing advanced materials optimized for biological drugs. Using our patented process, engineering, and materials science technologies, we've created a hybrid material that fuses all the benefits of glass with all the benefits of plastic, while eliminating the drawbacks of both. The material is a medical-grade polymer fused with a three-layer barrier system that protects contents from oxygen, moisture, leachables, and any compounds that can originate from the environment, the polymer, and label adhesives. Metal ions, leachables, and particles are seen commonly in conventional glass vials are virtually eliminated. The unique, patented vial provides an inert container for drugs and eliminates important problems facing biologic drug development. It eliminates contaminants associated with an immunogenic response such as subvisible particles and metal ions Ensures an oxygen and moisture barrier of glass with thermal stability down to -196 degrees centigrade Exhibits no leachable or extractable Exhibits no glass delamination .And is unbreakable even at cryogenic temperatures. All of these attributes make the SiO2 vials ideal for bioengineered vaccines, cell & gene therapies, and antibody-drug conjugates. Tuba: Apart from Moderna, who else are you working with that you can publicly mention? Lawrence: We can publicly only mention Moderna for Covid. We are working with a number of other covid vaccine and therapeutic manufacturers. They are testing our vials in their clinical trials. Beyond Covid, we have been working with Novartis and many other leading pharma companies. Tuba: Can you share other insights with our readers about the SiO2's growth? Lawrence: We have grown from 100 employees to over 500 employees. We have grown from 1 factory to 4 factories. All this was done in the last 6 months of 2020. Our growth continues as we support not only Covid but many other companies developing advanced biological drugs and therapies. Main Image Source: The Conversation About Author: Mr. Ganti looks after the day-to-day operations of SiO2 Materials Science. He brings more than 25 years of building commercial organizations, leading billion-dollar P&Ls, creating award-winning marketing campaigns, and driving growth initiatives in the Pharmaceutical, Consumer Products, and Data Analytics space. Related Post: ViewPoints Interview: Biogen's Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza
VIEWPOINTS

PharmaShots Interview: SiO2’s Lawrence Ganti Shares Insight on the Efforts to Scale Up the Manufacturing of Vials for COVID-19 Vaccines

In an interview with PharmaShots, Lawrence Ganti, President & Chief Business Officer at SiO2 Materials Science shared his views on the efforts to scale up the manufacturing of vials to combat COVID-19. Additionally, he also shared the benefits of using SiO2's smart vials and shed light on barrier technology. Shots: SiO2 received a $143M investment from the US government to scale the domestic…
March 22, 2021

Read more

Viewpoints_Tillman Gerngross
VIEWPOINTS

PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19

In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company expects ADG20 to enter clinical studies…
March 1, 2021

Read more

Viewpoints_Nathalie Landry
VIEWPOINTS

PharmaShots Interview: Medicago’s Nathalie Landry Shares Insight on Plant-Derived Vaccine for COVID-19

In an interview with PharmaShots, Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago shared her views on positive results of P-I clinical trial results for its plant-derived COVID-19 vaccine.  Shots: The results of the trial demonstrated that 100% of participants developed a promising antibody response after two doses of Medicago's COVID-19 adjuvanted vaccine candidate The vaccine…
February 15, 2021

Read more

Insight+_Senior Editor
INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2020

The third quarter of 2020 was flooded with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisitions, Gilead acquired Immunomedics for ~$21B, Illumina acquired GRAIL for ~$8B, J&J acquired Momenta Pharmaceuticals for $6.5B and Nestlé acquired Aimmune Therapeutics for $2.6B, Sanofi acquired Principia Biopharma for ~$3.68B. Apart from…
October 29, 2020

Read more

Viewpoint_Dr. Neil Collinson_2020
VIEWPOINTS

PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza

In a recent interview with PharmaShots, Dr. Neil Collinson, the Senior Principal Clinical Development Scientist at Genentech / Roche shares his insights and highlights on Xofluza. Shots: The P-III BLOCKSTONE study demonstrated that the proportion of household members who became symptomatically ill following infection with influenza was significantly lower in those treated preventively with Xofluza…
September 22, 2020

Read more

Thoughtspot_Dr. Anish Desai
THOUGHTSPOT

COVID-19 Treatment in India and Abroad

In late 2019, a mysterious virus causing infection consisting of dry cough, fever tiredness, and last pneumonia first appeared in Wuhan, China. The world health organization (WHO) named the disease as Coronavirus 2019 (Covid-19). Interestingly, Covid-19 and flu (caused by influenza virus) share the common disease progression asymptomatic (no symptoms), mild symptoms fever or chills,…
September 15, 2020

Read more

Load more